aTyr Pharma, Inc. (ATYR)
aTyr Pharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
aTyr Pharma, Inc. (ATYR) is a Biotechnology company based in US with a market capitalization of $47.6M. Revenue declined 19.1% year-over-year and free cash flow was negative at -$62.1M. This page tracks ATYR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 56 employees · IPO May 7, 2015
Valuation
Valuation & price
$0.50as of May 17, 2026· -91.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.71
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$47.6M
Market cap
-19.1%
Revenue growth (YoY)
-717.4%
Gross margin
-$62.1M
Free cash flow (USD)
-$66.7M
Net debt
Net cash position
25.2%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.11)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is aTyr Pharma, Inc.'s market cap?
aTyr Pharma, Inc. (ATYR) has a market capitalization of $47.6M.
What is ATYR's P/E ratio?
A meaningful P/E ratio is not available for ATYR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ATYR's price-to-book (P/B) ratio?
ATYR trades at 0.71 times book value per share.
When did aTyr Pharma, Inc. last report earnings?
ATYR last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying ATYR stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at aTyr Pharma, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.